FOFA
Family Office of America Inc.0.2600
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
7.72MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Family Office of America posted a Q3 net loss of $50,944, up from $22,676 y/y, on zero revenues while ramping pre-launch costs—operating expenses jumped 157% to $55,169, driven by warrants for services ($14,738) and stock-based comp to related parties ($14,270). Nine-month loss widened to $249,493 from $70,064 y/y as expenses tripled on equity incentives. Cash swelled to $827,598, fueled by $915,000 from stock sales, flipping equity positive at $803,665; no debt remains after CEO note conversion. Signed Oct 1 asset purchase for non-attest accounting assets from Toone & Associates for $1.5M (cash installments), retaining consultant for two years at $216,000 annually. EPS reconciles; warrants anti-dilutive. Competition shadows CPA consolidation plays.
8-K
Closes $1.5M asset buy
Family Office of America closed its $1.5M acquisition of Toone & Associates' accounting service assets on October 3, 2025, paying $750K upfront with $450K due October 1, 2026, and $300K on May 1, 2027. Price is subject to downward adjustment based on post-closing 12-month revenues and EBITDA. Deal bolsters accounting capabilities. Risks hinge on asset performance.
10-Q
Q2 FY2025 results
Family Office of America posted zero revenues for Q2 FY2025 ended June 30, 2025, with operating loss widening to $99,318 (up 230% y/y from $30,102) and net loss to $95,228 (up 205% y/y from $31,228), driven by warrants for services ($34,540) and stock-based comp-related parties ($14,270). Six-month net loss hit $198,549 (up 320% y/y), fueled by elevated equity comp while interest income offset $4K. Cash jumped to $585K from stock sales ($655K raised), flipping equity positive at $554K; short-term note payable to CEO stands at $9,627. Cash burn quickens. Diluted EPS aligns with shares outstanding; anti-dilution flagged. Warrants dilute heavily. No revenue yet.
10-Q
Q1 FY2025 results
Family Office of America posted a $103k net loss for Q1 FY2025 ended March 31, 2025, up from $16k a year earlier, driven by $104k operating expenses—mostly $92k consulting fees—versus none prior. No revenue yet, as the pre-revenue firm pivots to CPA acquisitions and family office services. Cash jumped to $565k from $14k q/q via $575k stock issuance, yielding $521k working capital; short-term CEO note steady at $10k, 10% rate. Warrants to insiders added $73k non-cash charge. Diluted EPS holds at $(0.00) with anti-dilutive effects flagged. Cash burn quickened. Succession risks loom for retiring CPAs.
10-K
FY2024 results
Family Office of America posted FY2024 net loss of $100,484, sharply improved from $805,021 in FY2023, driven by slashed operating expenses to $96,513 (down 58.1%) after cutting stock-based comp and R&D while refocusing admin. No revenues either year as SOLACE device awaits FDA clearance; Q4 2023 saw $76,008 asset impairment from manufacturer failure. Cash ended at $13,586 after $100,000 stock raise, yet working capital deficit persists at $23,440 with $89,370 operating burn. No buybacks or dividends. Going concern in doubt without funding. Disclosure controls ineffective.
IPO
Sector
Industry
AMIX
Autonomix Medical, Inc.
0.63-0.03
BWAY
Brainsway Ltd.
16.87-0.47
EMED
Electromedical Technologies, In
0.00+0.00
NMTC
NeuroOne Medical Technologies C
0.71+0.05
PROF
Profound Medical Corp.
7.55-0.14
SNWV
SANUWAVE Health, Inc.
31.46-0.18
STME
Stimcell Energetics, Inc.
0.37-0.04
VERO
Venus Concept Inc.
2.26+0.59
VVOS
Vivos Therapeutics, Inc.
2.02+0.00
ZOMDF
Zomedica Corp.
0.11+0.00